Irish digital therapeutics company HealthBeacon has entered into a multi-year commercial arrangement with one of the largest independent pharmacy benefits managers in the United States.
The company, which develops products for managing injectable medications for patients in the home, said the deal would make its injection care management system more widely available to the nine million patients in the US who self-administer injections at home.
HealthBeacon said its most recent peer-reviewed published evidence demonstrated up to a 26 per cent improvement in injectable medication adherence.
Through the new contract, HealthBeacon expects to deploy up to 15,000 units this year of its Smart Sharps Bin, a product that tracks and has been “clinically proven to materially enhance patient adherence with medication schedules”.
‘Significant milestone’
The company has a near-term target of 100,000 patients using its injection system, representing an approximately 10-fold increase on the number of units deployed by HealthBeacon at the end of 2021.
HealthBeacon chief executive Jim Joyce said: "The signing of this contract is a significant milestone for HealthBeacon. It is also an important validation of HealthBeacon's technology and the clinical effectiveness of our product.
“Moreover, it is an endorsement of our mission to become the world’s leading digital therapeutics platform for injectable medications.”
In the initial rollout of the agreement, pharmaceutical manufacturers will have “streamlined and integrated access” to this adherence technology through specialty pharmacies.
